Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10716626 | 0.80 | TSHR (0.38) | TSHRRGS12TDP1BACE1 | |
| SCHEMBL28865121 | 0.72 | TSHR (0.36) | TSHRRGS12 | |
| SCHEMBL3796662 | 0.71 | — | — | |
| SCHEMBL6234607 | 0.67 | TSHR (0.43) | TSHRRGS12TDP1BACE1 | |
| SCHEMBL11537769 | 0.67 | TSHR (0.47) | TSHRRGS12BACE1 | |
| SCHEMBL6230585 | 0.67 | TSHR (0.43) | TSHRRGS12BACE1 | |
| SCHEMBL631670 | 0.65 | TSHR (0.41) | TSHRRGS12BACE1 | |
| SCHEMBL6233114 | 0.64 | ALDH1A1 (0.46) | TSHRRGS12TDP1 | |
| SCHEMBL1727964 | 0.64 | — | — | |
| SCHEMBL10040702 | 0.62 | TSHR (0.38) | TSHRRGS12TDP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5830867-A | Hemoregulatory peptides for stimulating the myelopoietic system | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-03 | — | — | US | claimed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | claimed |
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2134342-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-6900213-B2 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1351941-B1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA, LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1351941-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002070493-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-5830867-A | Hemoregulatory peptides for stimulating the myelopoietic system | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| US-4741818-A | COMPLEXES | LEARONAL, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| EP-0225422-A1 | Alkaline baths and methods for electrodeposition of palladium and palladium alloys | LeaRonal, Inc. (US) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | FSHR, GNRHR, LHCGR | TSHR 30/4885RGS12 604/4885TDP1 3565/4885 |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | TSHR 725/4885RGS12 367/4885TDP1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.